Ilyang Pharm (007570) - Total Assets
Based on the latest financial reports, Ilyang Pharm (007570) holds total assets worth ₩444.81 Billion KRW (≈ $301.44 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ilyang Pharm - Total Assets Trend (2002–2024)
This chart illustrates how Ilyang Pharm's total assets have evolved over time, based on quarterly financial data. Also see how much is Ilyang Pharm worth for the company's overall valuation and market capitalisation.
Ilyang Pharm - Asset Composition Analysis
Current Asset Composition (December 2024)
Ilyang Pharm's total assets of ₩444.81 Billion consist of 29.1% current assets and 70.9% non-current assets. Review Ilyang Pharm debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 1.0% |
| Accounts Receivable | ₩44.96 Billion | 10.4% |
| Inventory | ₩59.87 Billion | 13.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩25.34 Billion | 5.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how Ilyang Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 007570 stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ilyang Pharm's current assets represent 29.1% of total assets in 2024, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 1.0% of total assets in 2024, up from 0.7% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 2.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 13.9% of total assets.
Ilyang Pharm Competitors by Total Assets
Key competitors of Ilyang Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Ilyang Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.87 | 0.88 | 0.97 |
| Quick Ratio | 0.42 | 0.51 | 0.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-20.45 Billion | ₩-24.77 Billion | ₩-6.33 Billion |
Ilyang Pharm - Advanced Valuation Insights
This section examines the relationship between Ilyang Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 20.9% |
| Total Assets | ₩431.21 Billion |
| Market Capitalization | $96.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ilyang Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Ilyang Pharm's assets grew by 20.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ilyang Pharm (2002–2024)
The table below shows the annual total assets of Ilyang Pharm from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩431.21 Billion ≈ $292.23 Million |
+20.90% |
| 2023-12-31 | ₩356.66 Billion ≈ $241.70 Million |
-28.41% |
| 2022-12-31 | ₩498.19 Billion ≈ $337.61 Million |
+0.79% |
| 2021-12-31 | ₩494.27 Billion ≈ $334.96 Million |
+12.56% |
| 2020-12-31 | ₩439.12 Billion ≈ $297.58 Million |
+0.38% |
| 2019-12-31 | ₩437.46 Billion ≈ $296.46 Million |
+1.20% |
| 2018-12-31 | ₩432.25 Billion ≈ $292.93 Million |
-0.94% |
| 2017-12-31 | ₩436.37 Billion ≈ $295.72 Million |
+1.19% |
| 2016-12-31 | ₩431.26 Billion ≈ $292.26 Million |
-0.08% |
| 2015-12-31 | ₩431.63 Billion ≈ $292.51 Million |
+0.18% |
| 2014-12-31 | ₩430.83 Billion ≈ $291.97 Million |
+8.14% |
| 2013-12-31 | ₩398.38 Billion ≈ $269.98 Million |
+37.44% |
| 2009-12-31 | ₩289.86 Billion ≈ $196.44 Million |
+52.13% |
| 2004-12-31 | ₩190.53 Billion ≈ $129.12 Million |
+13.21% |
| 2003-12-31 | ₩168.29 Billion ≈ $114.05 Million |
-3.41% |
| 2002-12-31 | ₩174.24 Billion ≈ $118.08 Million |
-- |
About Ilyang Pharm
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, anti… Read more